qav-680
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00784732)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- G protein-coupled receptor 44ANTAGONIST
PTGDR2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1- Mol. weight
- 358.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2442750 ↗
Also known as
- nvp-qav680
- nvp-qav680
- qav680
- qav680
- qav680
- qav-680
- qav-680
- qav-680
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01103050 | Phase 2 | Mar 22, 2010 | Novartis |
| NCT01103037 | Phase 2 | Mar 1, 2010 | Novartis |
| NCT00814216 | Phase 2 | Dec 1, 2008 | Novartis |
| NCT00784732 | Phase 2 | Sep 1, 2008 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 1 | 2008 |
1 organizations
Page 1 / 1